Biotech Volatile Movements: CEL-SCI (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), Alder Biopharmaceuticals (NASDAQ:ALDR), CytRx (NASDAQ:CYTR), StemCells Inc (NASDAQ:STEM)

CEL-SCI Corporation (NYSEMKT:CVM) announced that Geert Kersten Chief Executive Officer will be presenting at the 2014 BIO International Convention on Wednesday June 25th at 2:00 p.m. PDT. Hosted by the Biotechnology Industry Organization (BIO) this year’s global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego California. CEL-SCI Corporation (NYSEMKT:CVM) stock performance was -6.40% in last session and finished the day at $1.17. Traded volume was 811,061.00million shares in the last session and the average volume of the stock remained 798.33K shares. The beta of the stock remained 1.58. CEL-SCI Corporation (NYSEMKT:CVM) insider ownership is 1.40%.

NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, demonstrated continuing progress with its IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor program at the American Society for Clinical Oncology (ASCO) 2014 annual meeting. NewLink Genetics Corp (NASDAQ:NLNK) rose 1.76 percent to $26.58 Tuesday on volume of 594,946.00million shares. The intra-day range of the stock was $26.12 to $28.58. NewLink Genetics Corp (NASDAQ:NLNK) has a market capitalization of $740.90million.

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its earnings data on Wednesday. The company reported ($5.38) EPS for the quarter, Analyst Ratings.Net reports. The company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $4.60 million. Alder Biopharmaceuticals Inc (NASDAQ:ALDR)’s stock on June 24, 2014 reported a decrease of -2.71% to the closing price of $18.32. Its fifty two weeks range is $9.50 -$22.95. The total market capitalization recorded $564.32million. The overall volume in the last trading session was 193,628.00million shares. In its share capital, ALDR has 29.91million outstanding shares.

CytRx Corporation (NASDAQ:CYTR) on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). On Tuesday, shares of CytRx Corporation (NASDAQ:CYTR) dropped -6.88% to close the day at $4.33. Company return on investment (ROI) is -257.90% and its monthly performance is recorded as 13.65%. CytRx Corporation (NASDAQ:CYTR) quarterly revenue growth is 17.34%.

StemCells Inc (NASDAQ:STEM) on June 9 announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. StemCells Inc (NASDAQ:STEM) stock performance was -6.12% in last session and finished the day at $1.84. Traded volume was 3.84million shares in the last session and the average volume of the stock remained 1.62million shares. The beta of the stock remained 1.47. StemCells Inc (NASDAQ:STEM) insider ownership is 5.90%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone